Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 5/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17364083 | 0.93 | PTGDR2 (0.38) | PTGDR2RBP4PTGFRBACE1NPC1 | |
| SCHEMBL15994984 | 0.88 | BACE1 (0.35) | PTGDR2RBP4PTGFRBACE1NPC1 | |
| SCHEMBL17004603 | 0.86 | BACE1 (0.36) | PTGDR2BACE1NPC1ALDH1A1LMNA | |
| SCHEMBL17004602 | 0.86 | BACE1 (0.36) | PTGDR2BACE1NPC1ALDH1A1LMNA | |
| SCHEMBL17004601 | 0.86 | BACE1 (0.36) | PTGDR2BACE1NPC1ALDH1A1LMNA | |
| SCHEMBL19296129 | 0.86 | BACE1 (0.35) | PTGDR2BACE1ALDH1A1LMNA | |
| SCHEMBL15999901 | 0.84 | ALDH1A1 (0.34) | BACE1ALDH1A1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL15991534 | 0.84 | BACE1 (0.45) | PTGDR2RBP4BACE1NPC1ALDH1A1 | |
| SCHEMBL21433323 | 0.84 | BACE1 (0.45) | PTGDR2RBP4BACE1NPC1ALDH1A1 | |
| SCHEMBL2591587 | 0.83 | BACE1 (0.36) | PTGDR2BACE1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194396-B1 | DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9868738-B2 | Diazine-fused amidines as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170247377-A1 | DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3194396-A1 | DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044120-A1 | DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247377-A1 | DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | PTGDR2 2966/4885RBP4 2600/4885PTGFR 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.